COVVI

COVVI operates in the upper-limb prosthetics and assistive medical-device market, with a focused proposition built around the COVVI Hand rather than a broad digital-health platform. Its differentiation is primarily product architecture and ecosystem depth: the hand is multi-articulating, supports programmable grip patterns, and is offered with straight-wrist and friction-wrist configurations. The company also supplies batteries, wrist assemblies, chargers, replacement gloves, and installation components, which can improve continuity for clinicians, prosthetic providers, and users. COVVI Go adds a software layer for configuration, remote updates, and diagnostic support. The website also identifies Free Lock prosthetic, paediatric orthotic, and cycling-grip products, extending the company beyond a single bionic-hand product. There is also no disclosed market-share, reimbursement, revenue, or clinical-outcomes data. The 2026 One-to-Watch award supports recognition within the regional healthcare-technology community, but COVVI’s competitive position should be viewed as an emerging specialist position, with differentiation grounded in configurable hardware, supporting components, and a connected clinical-user workflow.

COVVI’s trajectory shows a progression from founding in August 2017 to building a specialist upper-limb prosthetics business centered on the COVVI Hand. The company’s offering has expanded beyond the core hand to include multiple wrist configurations, batteries, chargers, replacement parts, and the COVVI Go application. That combination indicates an effort to develop a complete product and service ecosystem rather than sell a standalone device. Hiring is the clearest operating-growth signal: 30 open positions were reported in April 2023, followed by continued team growth through 2024, while no layoffs were reported. The Nov 12, 2022 coverage of Leeds-based design and production points to an emphasis on in-house or closely managed manufacturing capability. Recognition at the Medilink North of England Healthcare Business Awards, with the award dated Apr 30, 2026 and announced May 7, 2026, is a further validation point for the company’s emerging status. Growth remains difficult to quantify because no funding rounds, valuation, revenue figures, or investor base are disclosed. The available evidence supports steady product and team development, but not a conclusion of rapid financial scale-up.